Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Francisco J. Chacón-Lozsán
MD student UCLA-Venezuela
European Society of Cardiology:
Heart Failure Association
Acute Cardi...
Heart Failure (HF) Is a clinic condition which
the cardiac output in not adequate to supply
the tissue needs.
Framingham
Major Criteria

Minor Criteria

Major and minor criteria

•Orthopnea or nocturnal
paroxysmal dyspnea.
•Neck vei...
AHA functional stratification of HF
Clinic presentation

Characteristics

Objectives

SBP >160mmHg

Pulmonary congestion without
systemic congestion. Many
wit...
Presentación clínica

Características

Objetivos

Acute pulmonary edema.

Abrupt, impaired by severe
hyperventilation. Pat...
ACE inhibitor (candesartan preferably)

+Beta-Blocker

If NYHA II-IV add MRA (spironolactone)

+Ivabradine (If using BB HR...
Heart failure quick guide 2013
Heart failure quick guide 2013
Heart failure quick guide 2013
Heart failure quick guide 2013
Heart failure quick guide 2013
Heart failure quick guide 2013
Heart failure quick guide 2013
Heart failure quick guide 2013
Heart failure quick guide 2013
Heart failure quick guide 2013
Heart failure quick guide 2013
Heart failure quick guide 2013
Upcoming SlideShare
Loading in …5
×

Heart failure quick guide 2013

1,280 views

Published on

Heart Failure Quick Guide 2013.
Diagnosis and management.

Published in: Education, Health & Medicine
  • Be the first to comment

Heart failure quick guide 2013

  1. 1. Francisco J. Chacón-Lozsán MD student UCLA-Venezuela European Society of Cardiology: Heart Failure Association Acute Cardiovascular Care Association LinkedIn: http://ve.linkedin.com/in/chaconlozsanfrancisco 2013
  2. 2. Heart Failure (HF) Is a clinic condition which the cardiac output in not adequate to supply the tissue needs.
  3. 3. Framingham Major Criteria Minor Criteria Major and minor criteria •Orthopnea or nocturnal paroxysmal dyspnea. •Neck veins distension. •Crackles. •Cardiomegaly. •Acute pulmonary edema. •3 Cardiac murmur. •CVP >6cmH2O •Hepatic-Jugular reflux. •Lower extremities bilateral edema, nocturnal cough or efforts dyspnea. •Hepatomegaly •Pulmonary vital capacity reduced 50% •HR>120/min •Weigh loss >4,5Kg with treatment.
  4. 4. AHA functional stratification of HF
  5. 5. Clinic presentation Characteristics Objectives SBP >160mmHg Pulmonary congestion without systemic congestion. Many with Ejection Fraction (EF) preserved. Objective: Volume management. BP control. Therapy: Vasodilator and loop diuretics. Normal BP or moderate high BP (>160mmHg). Gradual depression associated to systemic congestion. Radiologic pulmonary congestion in patients with advanced HF. Objective: Volume management. Therapy: Vasodilator with or without loop diuretics. Low BP (>90mmHg) Related to low cardiac output with depression of renal function. Objective: Cardiac output. Therapy: Cardiac inotropic with vasodilator properties, consider digoxin, vasodilators and mechanical assistance. Cardiogenic Shock. Fast, complicated with MI, fast myocarditis, acute valvular disease. Objective: Rise pump function. Therapy: vasoactive drugs, Inotropic and mechanical assistance.
  6. 6. Presentación clínica Características Objetivos Acute pulmonary edema. Abrupt, impaired by severe hyperventilation. Patient responses fast to vasodilators and diuretics. Objective: Volume management. Therapy: Vasodilators, diuretics, ventilation, morphine. ACS with acute HF Many patients have sings and symptoms of HF that get better resolving ischemia. Objectives: Thrombolysis, plaque stabilization, ischemic correction. Therapy: Reperfusion by PCI, lysis, nitrates, antipatelet agents. Isolated Right HF IC or intrinsic RV failure or valvular disease. Rapid of gradual, primary or secondary to HBP or RV pathology. Objective: BP management. Therapy: Nitrates, phosphodiesterase inhibitors, endoteline inhibitors, RV MI reperfusion, valvular surgery. HF post cardiac surgery. Can be caused by inadequate myocardial protection resulting in cardiac damage. Objective: Volume management, rise CO. Therapy: Use diuretic or fluids, inotropic, mechanical assistance.
  7. 7. ACE inhibitor (candesartan preferably) +Beta-Blocker If NYHA II-IV add MRA (spironolactone) +Ivabradine (If using BB HR>70/min) Still NYHA II-IV: Consider Pacemaker • If QRS > 0,12sec use resynchronization. • If QRS < 0,12sec use Automatic Implantable Defibrillator. If still NYHA II-IV add Digoxin.

×